Trials / Recruiting
RecruitingNCT06701513
A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
Registry of Psoriasis Health Outcomes: A Longitudinal Real-world Collaboration (RePhlect) - A Real-world, Prospective, Observational Study of the Effectiveness of Deucravacitinib in Adults With Moderate-to-Severe Plaque Psoriasis in France
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 350 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this study is to assess the real-world effectiveness of deucravacitinib treatment in adults diagnosed with moderate-to-severe plaque psoriasis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | As prescribed by treating clinician |
Timeline
- Start date
- 2025-01-29
- Primary completion
- 2028-04-30
- Completion
- 2028-04-30
- First posted
- 2024-11-22
- Last updated
- 2025-04-11
Locations
40 sites across 2 countries: France, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06701513. Inclusion in this directory is not an endorsement.